TARO vs. PTGX, DVAX, HRMY, AVDL, SUPN, AMRX, ZLAB, GPCR, ARDX, and EWTX
Should you be buying Taro Pharmaceutical Industries stock or one of its competitors? The main competitors of Taro Pharmaceutical Industries include Protagonist Therapeutics (PTGX), Dynavax Technologies (DVAX), Harmony Biosciences (HRMY), Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), Amneal Pharmaceuticals (AMRX), Zai Lab (ZLAB), Structure Therapeutics (GPCR), Ardelyx (ARDX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical preparations" industry.
Taro Pharmaceutical Industries (NYSE:TARO) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
Taro Pharmaceutical Industries received 27 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 61.64% of users gave Taro Pharmaceutical Industries an outperform vote while only 59.54% of users gave Protagonist Therapeutics an outperform vote.
Taro Pharmaceutical Industries has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Taro Pharmaceutical Industries has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500.
In the previous week, Protagonist Therapeutics had 4 more articles in the media than Taro Pharmaceutical Industries. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 1 mentions for Taro Pharmaceutical Industries. Protagonist Therapeutics' average media sentiment score of 0.64 beat Taro Pharmaceutical Industries' score of 0.24 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
91.4% of Taro Pharmaceutical Industries shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 13.8% of Taro Pharmaceutical Industries shares are held by insiders. Comparatively, 5.0% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Taro Pharmaceutical Industries has a net margin of 7.48% compared to Protagonist Therapeutics' net margin of 0.00%. Taro Pharmaceutical Industries' return on equity of 3.26% beat Protagonist Therapeutics' return on equity.
Taro Pharmaceutical Industries currently has a consensus target price of $43.00, suggesting a potential upside of 1.42%. Protagonist Therapeutics has a consensus target price of $36.00, suggesting a potential upside of 43.14%. Given Protagonist Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protagonist Therapeutics is more favorable than Taro Pharmaceutical Industries.
Summary
Taro Pharmaceutical Industries beats Protagonist Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Taro Pharmaceutical Industries News Delivered to You Automatically
Sign up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TARO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taro Pharmaceutical Industries Competitors List
Related Companies and Tools
